Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
Meet the European experts leading this activity and learn how they use ICIs and manage immune-related adverse events to optimally manage patients with previously treated HCC.
From Clinical Care Options (CCO), download slides reviewing the integration of CAR T-cell therapy into community care
Experts describe key takeaways from a live symposium on HER2-, HER3-, and TROP2-targeted therapies and treatment approaches for patients, from Clinical Care Options (CCO)
Patient-reported outcomes from the HIMALAYA study of durvalumab with or without tremelimumab vs sorafenib in unresectable hepatocellular carcinoma, presented at ASCO 2022 and reported by Clinical Care Options (CCO)
Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for pancreatic and biliary tract cancers